<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02259920</url>
  </required_header>
  <id_info>
    <org_study_id>1207.2</org_study_id>
    <nct_id>NCT02259920</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers</brief_title>
  <official_title>Open Label, Randomized, Single-dose, Five-way Crossover Study to Investigate the Regional Drug Absorption of 80 mg KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine and compare the absorption of KUC 7483 CL from different regions of the GI&#xD;
      tract with the immediate release formulation and to compare the absorption of particulate&#xD;
      versus solution formulations from the ascending colon&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax(maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant of the analyte constant in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo (mean residence time of the analyte in the body after oral administration)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in the plasma after extravascular administration)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet1-t2 (amount of the analyte that is eliminated in urine from the time point t1 until time point t2)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fet1-t2 (fraction of administered drug excreted unchanged in urine from the time point t1 until time point t2)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,t1-t2 (renal clearance of the analyte determined from the time point t1 until time point t2)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 8 days after last drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>KUC 4783 CL, immediate release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KUC 4783 CL delivered as a particulate formulation to the distal small bowel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KUC 4783 CL delivered as a particulate formulation to the ascending colon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KUC 4783 CL delivered as a solution formulation to the ascending colon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KUC 4783 CL delivered as a solution formulation to the descending colon</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KUC 7483 CL, immediate release tablet</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KUC 7483 CL, particulate formulation</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KUC 7483 CL, solution formulation</intervention_name>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_label>Treatment E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Enterion™ capsule</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_label>Treatment E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males, according to the following criteria:&#xD;
&#xD;
             Based upon a complete medical history, including the physical examination, vital signs&#xD;
             (blood pressure (BP), pulse rate (PR)), 12-lead ECG, clinical laboratory tests&#xD;
&#xD;
               -  No clinically significant findings&#xD;
&#xD;
               -  No evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          2. Age ≥18 and ≤65 years&#xD;
&#xD;
          3. BMI ≥18.5 and ≤29.9 kg/m2&#xD;
&#xD;
          4. Subjects must be able to demonstrate the ability to swallow an empty size 000 gelatin&#xD;
             capsule&#xD;
&#xD;
          5. Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with Good Clinical Practice and the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          2. History of gastrointestinal surgery, with the exception of Appendicectomy unless it&#xD;
             was performed within the previous 12 months&#xD;
&#xD;
          3. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             neurological disorders&#xD;
&#xD;
          4. History of relevant orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          5. Chronic or relevant acute infections&#xD;
&#xD;
          6. History of allergy/hypersensitivity (including drug allergy) to any drug including the&#xD;
             study drug (KUC-7483 CL) and similar drugs which is deemed relevant to the trial as&#xD;
             judged by the investigator&#xD;
&#xD;
          7. Use of prescription or non-prescription drugs (including vitamins and natural herbal&#xD;
             remedies e.g. St Johns Wort) from 14 days prior to the start of the study until the&#xD;
             end of the final study period. Occasional use of paracetamol (up to 4g per day) is&#xD;
             permitted throughout the study&#xD;
&#xD;
          8. Participation in another trial with an investigational drug within four months prior&#xD;
             to administration or during the trial&#xD;
&#xD;
          9. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day). A breath carbon monoxide&#xD;
             reading of greater than 20ppm&#xD;
&#xD;
         10. Inability to refrain from smoking on trial days&#xD;
&#xD;
         11. Regular alcohol consumption &gt;21 units per week units per week (1 Unit = ½ pint beer, a&#xD;
             25ml shot of 40% spirit or a 125ml glass of wine)&#xD;
&#xD;
         12. Subjects who have ever sought advice from a physician or counselor for abuse or misuse&#xD;
             of alcohol, non-medicinal drugs or other substances of abuse e.g. solvents&#xD;
&#xD;
         13. Any current or previous use of Class A drugs such as opiates, cocaine, ecstasy,&#xD;
             lysergic acid diethylamide, and amphetamines (Class B).&#xD;
&#xD;
             Volunteers who admit to occasional past use of cannabis will not be excluded as long&#xD;
             as they have a negative drugs of abuse test and have been abstinent for at least 12&#xD;
             months&#xD;
&#xD;
         14. Positive drugs of abuse result&#xD;
&#xD;
         15. Blood donation (more than 100 mL within three months prior to administration or during&#xD;
             the trial)&#xD;
&#xD;
         16. Excessive physical activities outside a subjects normal routine (within one week prior&#xD;
             to administration or during the trial until after the post-study medical)&#xD;
&#xD;
         17. Unable to eat all elements of a standard meal&#xD;
&#xD;
         18. Any laboratory value outside the reference range of clinical relevance as determined&#xD;
             by the Investigator&#xD;
&#xD;
         19. Radiation exposure from clinical trials, including that from the present study and&#xD;
             from diagnostic X-rays but excluding background radiation, exceeding 5mSv in the last&#xD;
             twelve months or 10mSv in the last five years. No subject whose occupational exposure&#xD;
             is monitored will participate in the study&#xD;
&#xD;
         20. Acute diarrhea, or constipation in the 14 days before the predicted first study day.&#xD;
             If screening occurs &gt;14 days before first study day, this criterion is to be&#xD;
             determined on first study day. Diarrhea will be defined as the passage of liquid&#xD;
             faeces and/or a stool frequency of greater than three times per day. Constipation will&#xD;
             be defined as a failure to open the bowels more frequently than every other day&#xD;
&#xD;
         21. Presence of non-removable metal objects such as metal plates, screws etc. in abdominal&#xD;
             region of the body&#xD;
&#xD;
         22. Subjects will be excluded from the study if they are considered by the investigator to&#xD;
             be at risk of transmitting through blood and other body fluids the agents responsible&#xD;
             for AIDS (Acquired Immunodeficiency Syndrome) or other sexually transmitted disease or&#xD;
             hepatitis. This will be achieved by the use of a card (similar to that used by the&#xD;
             National Blood Transfusion Service) which asks a potential subject if they have reason&#xD;
             to believe that they may fall into any category included on the card. If the verbal&#xD;
             answer is in the affirmative then they will be excluded from the study&#xD;
&#xD;
         23. Positive hepatitis B virus, hepatitis C virus or HIV results&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2014</study_first_posted>
  <last_update_submitted>October 7, 2014</last_update_submitted>
  <last_update_submitted_qc>October 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>p-Hydroxyamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02259920
org study id: 1207.2
nct id: NCT02259920
lead sponsor: 
Study to determine and compare the absorption of KUC 7483 CL from different regions of the GI
      tract with the immediate release formulation and to compare the absorption of particulate
      versus solution formulations from the ascending colon
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
time frame: up to 24 hours after drug administration
measure: Cmax(maximum measured concentration of the analyte in plasma)
time frame: up to 24 hours after drug administration
measure: tmax (time from dosing to the maximum concentration of the analyte in plasma)
time frame: up to 24 hours after drug administration
measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)
time frame: up to 24 hours after drug administration
measure: λz (terminal rate constant of the analyte constant in plasma)
time frame: up to 24 hours after drug administration
measure: t1/2 (terminal half-life of the analyte in plasma)
time frame: up to 24 hours after drug administration
measure: MRTpo (mean residence time of the analyte in the body after oral administration)
time frame: up to 24 hours after drug administration
measure: CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
time frame: up to 24 hours after drug administration
measure: Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
time frame: up to 24 hours after drug administration
measure: Aet1-t2 (amount of the analyte that is eliminated in urine from the time point t1 until time point t2)
time frame: up to 24 hours after drug administration
measure: fet1-t2 (fraction of administered drug excreted unchanged in urine from the time point t1 until time point t2)
time frame: up to 24 hours after drug administration
measure: CLR,t1-t2 (renal clearance of the analyte determined from the time point t1 until time point t2)
time frame: up to 24 hours after drug administration
measure: Number of subjects with adverse events
time frame: up to 8 days after last drug administration
arm group label: Treatment A
arm group type: Active Comparator
description: KUC 4783 CL, immediate release tablets
arm group label: Treatment B
arm group type: Experimental
description: KUC 4783 CL delivered as a particulate formulation to the distal small bowel
arm group label: Treatment C
arm group type: Experimental
description: KUC 4783 CL delivered as a particulate formulation to the ascending colon
arm group label: Treatment D
arm group type: Experimental
description: KUC 4783 CL delivered as a solution formulation to the ascending colon
arm group label: Treatment E
arm group type: Experimental
description: KUC 4783 CL delivered as a solution formulation to the descending colon
intervention type: Drug
intervention name: KUC 7483 CL, immediate release tablet
arm group label: Treatment A
intervention type: Drug
intervention name: KUC 7483 CL, particulate formulation
arm group label: Treatment B
arm group label: Treatment C
intervention type: Drug
intervention name: KUC 7483 CL, solution formulation
arm group label: Treatment D
arm group label: Treatment E
intervention type: Device
intervention name: Enterion™ capsule
arm group label: Treatment B
arm group label: Treatment C
arm group label: Treatment D
arm group label: Treatment E
criteria: 
gender: Male
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: Accepts Healthy Volunteers
url: http://trials.boehringer-ingelheim.com
description: Related Info
responsible party type: Sponsor
mesh term: p-Hydroxyamphetamine